Ampersand Biomedicines
Boston
About Ampersand Biomedicines
Ampersand Biomedicines is a multi-product platform that develops programmable medicines that target disease sites precisely. Utilizing a computational platform, Ampersand identifies ideal drug localization strategies, informing the design of targeted therapies known as AND-Body Therapeutics. The Address, Navigate, Determine (AND)™ Platform, driven by advanced computation, pinpoints optimal addresses for drug localization and guides the development of AND-Body™ Therapeutics, ensuring maximum therapeutic efficacy. This leads to more intelligent biologic medicines that specifically target diseased areas while sparing healthy tissues and cells.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $10K – $50K
- Total funding: $115.0M
- Funding stage: Early Stage Venture
- Last round: Series B (Mar 2025)
- Website: ampersand.bio
- Phone: [email protected]
Industries & Categories
Biopharma, Biotechnology, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/ampersand-biomedicines-50994 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.